Last $6.67 USD
Change Today -0.10 / -1.48%
Volume 59.3K
RGLS On Other Exchanges
As of 8:10 PM 07/21/14 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - $11.88
52 Week Low
05/9/14 - $5.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

regulus therapeutics inc (RGLS) Related Businessweek News

View More BusinessWeek News

regulus therapeutics inc (RGLS) Details

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which is chemically modified and single-stranded oligonucleotide. Its clinical candidate products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection. The company has strategic collaboration with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GlaxoSmithKline plc to discover and develop microRNA therapeutics for immuno-inflammatory diseases. It also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 pre-clinical fibrosis program for the treatment of alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

74 Employees
Last Reported Date: 05/9/14
Founded in 2007

regulus therapeutics inc (RGLS) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $600.0K
Chief Scientific Officer
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

regulus therapeutics inc (RGLS) Key Developments

Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer

Regulus Therapeutics Inc. announced the appointment of Paul C. Grint, M.D. to its executive management team as Chief Medical Officer. In his new role, Dr. Grint will be responsible for leading and expanding Regulus' microRNA clinical portfolio and will serve as a key member of its executive leadership team. Grint joined Regulus from Cerexa Inc. where he served as President and was responsible for the oversight of anti-infective product development.

Regulus Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Regulus Therapeutics Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenues under strategic alliances and collaborations of $1,631,000 against $3,238,000 a year ago. Loss from operations was $10,705,000 against $5,550,000 a year ago. Loss before income taxes was $12,740,000 against $7,239,000 a year ago. Net loss was $12,741,000 or $0.30 per basic and diluted share against $7,229,000 or $0.20 per basic and diluted share a year ago.

Regulus Therapeutics Inc. to Report Q1, 2014 Results on May 08, 2014

Regulus Therapeutics Inc. announced that they will report Q1, 2014 results at 5:00 PM, Eastern Standard Time on May 08, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $6.67 USD -0.10

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$1.11 AUD -0.04
Enzon Pharmaceuticals Inc $1.04 USD +0.01
Galena Biopharma Inc $2.79 USD +0.08
Silence Therapeutics PLC 221.00 GBp 0.00
Tekmira Pharmaceuticals Corp C$10.28 CAD +0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.1x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at